The abstract is read at the publisher; the summary is JClub's.
Finerenone slowed kidney function decline in 215 adults with focal segmental glomerulosclerosis, reducing total eGFR slope by 1.3 ml/min/1.73 m2/year versus placebo.
- Why it matters: Mineralocorticoid receptor overactivation is linked to podocyte injury and glomerulosclerosis, but efficacy and safety of finerenone specifically in FSGS needed clarification.
- What they did: In the FIND-CKD trial, 1584 adults with nondiabetic CKD were randomized 1:1 to finerenone (10 or 20 mg) or placebo on stable renin-angiotensin system inhibition, with prespecified FSGS subgroup analyses.
- The result: Finerenone lowered UPCR by 41% at month 12 versus placebo, increased odds of UPCR <700 mg/g (odds ratio 6.8), reduced fibrosis/inflammation/filtration-barrier markers, and had hyperkalemia-related adverse events in 15% vs 20%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.